Clinical research
Like the Grinch’s heart at Christmas, the Nasdaq Exchange grew a little bigger this week with multiple life science companies raising hundreds of millions of dollars in initial public offerings.
A dual treatment approach consisting of gemcitabine combined with AB Science’s masitinib was associated with significant increases in survival among patients with pancreatic cancer and pain.
The four promising treatments showed no effect on reducing mortality in ongoing Solidarity Trial.
It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.
Researchers with the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) published a letter in The New England Journal of Medicine describing the three-month immunogenicity levels in Moderna’s mRNA-1273 vaccine.
With 36 Janssen-sponsored studies and another nearly 50, it has supported, the Janssen Pharmaceutical Companies of Johnson & Johnson has a presence in more than 80 of the hematology studies presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, December 5-8.
While promising, the study showed no difference between this combination regimen and physician’s choice of topotecan or cyclophosphamide/doxorubicin/vincristine (CAV) in terms of overall survival (OS).
Topline results from Agios Pharmaceuticals’ Phase III ACTIVATE trial show that treatment with mitapivat was associated with a significantly greater hemoglobin response compared with placebo in patients with pyruvate kinase deficiency.
Shares of Axsome were up more than 7% in premarket trading after the company announced positive, long-term results from its Phase III Major Depressive Disorder study that sets the company up for potential regulatory approval.
Despite a number of anti-psychotic medications available, there are no approved drugs to address underlying cognitive development issues. Cerevance aims to change that.
PRESS RELEASES